Healthcare Industry News: ImmunoPulse
News Release - December 21, 2018
OncoSec Announces Appointment Of Joon Kim, J.D., To Board Of DirectorsSAN DIEGO and PENNINGTON, N.J., Dec. 21, 2018 -- (Healthcare Sales & Marketing Network) -- OncoSec Medical Incorporated (OncoSec) (NASDAQ: ONCS), a company developing intratumoral cancer immunotherapies, announced today that Joon Kim, J.D., a partner at Lee & Ko, has been appointed to OncoSec's Board of Directors. The appointment was made in parallel to the investment by Alpha Holdings, Inc. (kosdaq:117670) of $15 million at $1.50 share, which was completed on December 7, 2018. The appointment was effective December 20, 2018.
"This is an exciting time to join OncoSec as they are moving into late-stage development of their lead programs and beginning to see the broad potential of their pipeline," said Joon Kim, J.D., Board Member of OncoSec. "I look forward to bringing my deep expertise in corporate law to bear as they continue their mission."
"Joon brings more than 20 years of legal experience, including advising corporate clients on a broad range of litigation and transactional matters," said Daniel J. O'Connor, President and Chief Executive Officer of OncoSec. "His insights will be valuable to our Company as we continue to advance the development of TAVO™ towards commercialization for the treatment of a range of tumors."
Joon Kim is a highly accomplished attorney and partner in Lee & Ko's Corporate, International Litigation and Dispute Resolution, and White Collar Crime Practice Groups. Mr. Kim advises clients, both domestic and international, on a broad range of litigation, dispute-resolution and transactional matters. With a particularly strong background in representing clients in court proceedings, Mr. Kim has a comprehensive understanding of every stage of the litigation process, including all aspects of initial investigatory/discovery proceedings, settlement negotiations, hearings, motions, trials, evidentiary issues and the handling of post-judgment challenges and appeals.
Prior to joining Lee & Ko, Mr. Kim worked for several years as a litigation lawyer and served from 2008 to 2017 as a public prosecutor in California. Mr. Kim has first-chaired both jury and non-jury trials, and has been trained in all aspects of litigation. During his time as a public prosecutor, Mr. Kim also had the experience of serving in 2016 as a research fellow in Korea at the Institute of Justice, under the auspices of the Korea Ministry of Justice, where he worked together with Korean public prosecutors. Joon received his J.D. from Berkeley School of Law and his B.S. from the Berkeley School of Business.
In addition, the company has appointed Julie Shin, U.S. patent attorney and a member of Lee & Ko's Intellectual Property, Healthcare, and Life Sciences Practice Groups as a Board Observer. Ms. Shin has extensive experience with intellectual property matters, having advised and assisted clients in a broad range of legal contexts, including litigation, licensing and other transactions, due diligence, product clearance and opinions, and IP asset management. She received her J.D. from the University of Virginia School of Law and her B.S. from Yale University.
About OncoSec Medical Incorporated
OncoSec is a clinical-stage biotechnology company focused on developing cytokine-based intratumoral immunotherapies to stimulate the body's immune system to target and attack cancer. OncoSec's lead immunotherapy platform – TAVO™ (tavokinogene telseplasmid) – enables the intratumoral delivery of DNA-based interleukin-12 (IL-12), a naturally occurring protein with immune-stimulating functions. The technology, which employs electroporation, is designed to produce a controlled, localized expression of IL-12 in the tumor microenvironment, enabling the immune system to target and attack tumors throughout the body. OncoSec has built a deep and diverse clinical pipeline utilizing TAVO™ as a potential treatment for multiple cancer indications either as a monotherapy or in combination with leading checkpoint inhibitors; with the latter potentially enabling OncoSec to address a great unmet medical need in oncology: anti-PD-1 non-responders. Results from recently completed clinical studies of TAVO™ have demonstrated a local immune response, and subsequently, a systemic effect as either a monotherapy or combination treatment approach. In addition to TAVO™, OncoSec is identifying and developing new DNA-encoded therapeutic candidates and tumor indications for use with its ImmunoPulse® platform. For more information, please visit www.oncosec.com.
This press release contains "forward-looking statements" within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as "can," "may," "will," "suggest," "look forward to," "potential," "understand," and similar references to future periods.
Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based on management's current preliminary expectations and are subject to risks and uncertainties, which may cause our results to differ materially and adversely from the statements contained herein. Potential risks and uncertainties that could cause actual results to differ from those predicted include, among others, the following: uncertainties inherent in pre-clinical studies and clinical trials, such as the ability to enroll patients in clinical trials and the risk of adverse events; unexpected new data, safety and technical issues; our ability to raise additional funding necessary to fund continued operations; and the other factors discussed in OncoSec's filings with the Securities and Exchange Commission.
Undue reliance should not be placed on forward-looking statements, which speak only as of the date they are made. OncoSec disclaims any obligation to update any forward-looking statements to reflect new information, events or circumstances after the date they are made, or to reflect the occurrence of unanticipated events.
Source: OncoSec Medical
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.